FDA Speeds Up Generic Drug Approvals with Fewer Clinical Trials
Published Date: 11/20/2025
Notice
Summary
The FDA just dropped new draft guidance to help drug makers show their biosimilar products work like the original ones without always needing extra big clinical studies. This update affects companies developing biosimilar drugs, aiming to speed up approvals and save money by cutting unnecessary tests. Comments on this draft are open until January 20, 2026, so industry folks should jump in now to shape the final rules!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Draft Guidance Released for Biosimilars
The FDA published a draft guidance titled "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies." The guidance describes considerations for when comparative clinical studies with efficacy endpoints (CES) are needed to support a marketing application under section 351(k) of the Public Health Service Act.
Analytical Tests May Replace Some Clinical Trials
FDA states a comparative analytical assessment is generally more sensitive than a comparative efficacy study (CES) for detecting differences between a proposed biosimilar and its reference product. The draft guidance explains scientific considerations for determining when a CES may not be necessary to support a demonstration of biosimilarity.
Agency Seeks Comments on Cost Savings
FDA requests public comments on the draft guidance and specifically asks for comments on costs or cost savings the guidance may generate, including potential cost savings for biosimilar development programs that use a streamlined approach. Submit electronic or written comments by January 20, 2026 for consideration as the Agency develops the final guidance.
Guidance Is Non‑Binding; Alternatives Allowed
FDA states the draft guidance does not establish any rights and is not binding on FDA or the public. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in